Clinical trial · Observational
Immuno-molecular Approaches for Non-invasive Diagnosis of Prostate Cancer
Non-invasive Isolation and Characterization of Prostate Tumor Cells for Prostate Cancer Diagnosis
NCT04702633CI-TRIAL-00097611PROSTA-PAPcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to isolate and characterize tumor cells non-invasively from biological samples in patients with prostate cancer and demonstrate the ability to identify the presence and number of tumor cells before prostate biopsy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Clinical data | Other | — | UNRESOLVED |
| Results obtained by biopsy and MRI results. | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Confirmed diagnosis group
- description
- Patients with a diagnosis of prostate cancer (metastatic or advanced) before prostatectomy.
- interventionNames
- Other: Results obtained by biopsy and MRI results.
- Other: Clinical data
- label
- Pre-diagnosis group
- description
- Patients undergoing prostate biopsy in the context of prostate cancer diagnosis: PSA increases, and / or abnormal digital rectal examination (DRE) and / or an MRI detected signal.
- interventionNames
- Other: Results obtained by biopsy and MRI results.
- Other: Clinical data
Primary outcomes (1)
- measure
- Presence and number of prostate tumour cells in biological samples
- timeFrame
- One month after biopsy or until the histological diagnosis will be obtained
Eligibility
Eligibility (as posted)
- Sex
- Male
Show eligibility criteria text
Inclusion Criteria: * Patients with a diagnosis of localized or metastatic prostate cancer. * No prior or other oncological treatment. * Patients undergoing prostate biopsy in the context of prostate cancer diagnosis. * Patients with an elevation of PSA (Prostate Specific Antigen), an abnormality on the rectal examination and / or an MRI signal motivating a prostate biopsy, * Patients informed and not opposed to participating in the research Exclusion Criteria: * Patients not affiliated with French social security. * Patients unable to understand the protocol. * Patients diagnosed with another type of cancer within the past 5 years. * Patients prostatectomized and/or treated for prostate cancer. * Patients who wear a bladder catheter * Patients under guardianship or curatorship * Patients under AME
References
Publications (0)
Data not yet available
No reference posted for this study.